Aguilar RF, Ramírez A

Language: Spanish
References: 13
Page: 125-130
PDF size: 131.28 Kb.

ABSTRACT

A man who is unable to develop or sustain an erection sufficient for penetrative sexual intercourse is usually labelled “impotent” —a word that not only has pejorative implications, but also takes little account of the complex process of male sexual function. Erectile dysfunction (ED) is now the preferred term. The concerned clinician will consider a patient’s inability to develop an erect penis within a given psychological and behavioural context, and recognize that although isolated ED is by far the most common problem, reduced libido and impaired orgasmic or ejaculatory capacity may also coexist to varying degrees, each contributing to the patient’s loss of confidence and sense of inadequacy. Recently there has been a surge of interest in the causes and remedies for ED. It is hoped that the information contained in this article will help point the way towards an improved quality of life for the many sufferers of ED and their partners.

REFERENCES

1. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 150:54-61.

2. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.

3. Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: new insights and more questions. J Urol 1993; 149:1246-1255.

4. Wagner G, Saenz de Tejeda I. Update on male erectile dysfunction. Br Med J 1998; 316:678-82.

5. Kirby RS. Impotence: diagnosis and management of erectile dysfunction. BMJ 1994; 308:957-961.

6. 6.(IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997;49:822-830.

7. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for erectile dysfunction. Br J Urol 1996;78:257-261

8. Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol 1998;81:122-127.

9. Padma-Nathan H, Hellstrom WJG, Kaiser FE et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1-7.

10. Hatzichristou DG. Sildenafil citrate lessons learned from 3 years of clinical experience. Int J Impot Res 2002;14 (Suppl. 1):S43-S52

11. Arruda-Olson AM. Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. J Am Med Assoc 2002;287:719-25

12. Jackson G. Phosphodiesterase 5 inhibition: effects on the coronary vasculature. Int J Clin Pract 2001;55:183-8

13. Estudio sobre la seguridad a largo plazo del tadalafil. F. Montorsi, B. Verheyden, K. P. Junemann, I. Moncada, L. Valiquette, J. Denne y V. S. Watkins. J Urol 2003;169 (Supl. 4):245 (resumen 947).